Aurobindo Pharma Ltd (NSE:AUROPHARMA)
₹ 1227.4 41.7 (3.52%) Market Cap: 719.18 Bil Enterprise Value: 719.74 Bil PE Ratio: 21.89 PB Ratio: 2.33 GF Score: 92/100

Q3 2024 Aurobindo Pharma Ltd Earnings Call Transcript

Feb 12, 2024 / 03:00AM GMT
Release Date Price: ₹1018.65 (+1.55%)
Operator

Welcome to Aurobindo Pharma Q3 FY24 earnings call. Please note that all participant lines will be in listen-only mode and there will be an opportunity for you to ask questions after the opening remarks. Please note that this conference is being recorded. I now hand the conference over to the management for opening remarks. Thank you and over to you sir.

Shriniwas Dange
Aurobindo Pharma Limited - IR

Thank you, Vandith. Good morning and a warm welcome to our third quarter FY24 earnings call. I'm Shriniwas Dange from the Investor Relations team. We hope you have received Q3 FY24 financials in the press release that was sent out on Saturday these are also available on our website.

I would now like to introduce my senior management team on the call with us today represented by Dr. Satakarni Makkapati, CEO of Aurobindo Biosimilars, Vaccines and Peptides businesses and Director Aurobindo Pharma Limited; Mr. Yugandhar Puvvala, CEO of Eugia Pharma Specialties Limited; Mr. Swami Iyer, CEO, Aurobindo Pharma USA; Mr. V. Muralidharn, President, Europe Formulations

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot